This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Other PrEP regimens on the market require daily oral dosages or shots every few months, but the latest version is only administered twice a year. Now, the WHO’s aggressive goal to “ end HIV/AIDS ” by 2030 could be hampered by dramatic reductions in U.S. A long-time leader in vaccines, the U.K. While Enhertu pulled in about $3.8
billion by 2030, according to a market report. However, during the second half, the surge in demand for vaccines to fight the coronavirus enhanced the industry’s need for raw materials and product intermediates of API molecules. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. Trends Pharmacol Sci. 2024;45(5):406-418.
The second most commonly used pharmaceutical dosage form, capsules, are anticipated to be a $5.2 billion market by 2030, growing from a 2020 value of around $2.4 Compared with other oral solid dosage forms (OSDs), capsules also offer the easiest method to achieve fixed-dose combinations (FDCs) of incompatible drug substances.
Recent Videos Related Content Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report Susan Haigney June 30th 2025 Article The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.
million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). million (approximately US$1.99 million (approximately US$1.99 million (approximately US$1.99 The company said in June 2025 that it raised €11.25 million (US$12.9
POD is suitable for a wide range of products, including oral solid dosage forms, mAbs, and cell therapy. Worldwide Modular Facilities in Pharmaceutical and Biotechnology Industry to 2030 - Impact Analysis of COVID-19.” Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” 13 July 2021. 16 June 2020.
The financing round was co-led by Kurma Partners , WE Life Sciences , and the French Tech Seed Fund managed by Bpifrance , on behalf of the French government, under the France 2030 initiative. Additional participants included Argobio , Angelini Ventures , CARMA Fund , Capital Grand Est , and Sambrinvest.
billion) by 2030 (1). One-quarter of patients who suffer a hip fracture die within one year, Theramex said, with hip fractures costing NHS £2 billion (US$2.7 billion) per year and osteoporotic fractures presently accounting for more than £4.6 billion (US$6.3 billion) of direct costs to NHS, forecast to increase to £6 billion (US$8.2
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content